Cargando…

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma

Fluorescence in situ hybridization (FISH) evaluation is essential for initial risk stratification in multiple myeloma (MM). The presence of specific cytogenetic abnormalities (CA) confers a heterogeneity impact on prognosis. However, the cutoff values among different centers are not uniform. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Tiancheng, Qiang, Wanting, Lu, Jing, He, Haiyan, Liu, Jin, Li, Lu, Jiang, Hua, Fu, Weijun, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975077/ https://www.ncbi.nlm.nih.gov/pubmed/35402836 http://dx.doi.org/10.1097/BS9.0000000000000077

Ejemplares similares

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
por: Qiang, Wanting, et al.
Publicado: (2023)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Single‐cell RNA‐seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma
por: He, Haiyan, et al.
Publicado: (2022)

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)
por: Varshavsky Yanovsky, A., et al.
Publicado: (2023)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model
por: Yuan, Shuai, et al.
Publicado: (2023)

P926: ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA
por: Du, Juan, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma
por: He, Haiyan, et al.
Publicado: (2023)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
por: Khan, R, et al.
Publicado: (2015)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Development and validation of prognostic survival models in newly diagnosed Parkinson's disease
por: Macleod, Angus D., et al.
Publicado: (2017)

Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib-based treatment response and survival via the microRNA-608-mediated Wnt/β-catenin pathway
por: Li, Lu, et al.
Publicado: (2022)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
por: Tian, Ying, et al.
Publicado: (2018)

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
por: Dosani, T, et al.
Publicado: (2017)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ndg4bj6gg7uv9fc2dfhj0v1ggv